A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

Abroad (travel likely)RecruitingPHASE1

Conditions

Overweight or Obesity · Healthy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Collaborative Neuroscience Network - CNS, Los Alamitos, California, United States
Study coordinator · 714-799-7799
Contact: Principal Investigator (Steven Reynolds)
ICON Early Phase Services, San Antonio, Texas, United States
Study coordinator · 210-225-5437
Contact: Principal Investigator (Robert Bass)
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
Study coordinator · +65-64139811
Contact: Principal Investigator (Jeffer Hann Wei Pang)

Study leads

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

Overweight · Obesity

Abroad (travel likely)RecruitingPHASE1

Neuss, Germany · Mölndal, Sweden

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

Healthy Volunteer

Abroad (travel likely)RecruitingPHASE1

Anaheim, United States

A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

Overweight · Obesity

Abroad (travel likely)RecruitingPHASE1

Lenexa, United States

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection

Obesity · Overweight

Abroad (travel likely)RecruitingPHASE1

Hefei, China